Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck KGaA : Effect Pigments for Architecture: Merck Exhibits at the Middle East Coatings Show 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/05/2012 | 10:24am CEST

Darmstadt/Germany, March 5, 2012 - Merck will be presenting its effect pigments for architecture at the Middle East Coatings Show in Dubai from March 12 to 14, 2012. This exhibition is the most important platform for the coatings sector in the Middle East and the Gulf region. The focus of the exhibition will be on architectural applications, which have been seeing rapid growth in the region for the past several years. The trend toward gold and silver shades, which can currently be seen in lifestyle products and interior designs, is also being reflected in architecture.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
03/28 PFIZER : FDA Approves PD-L1 Immunotherapy Developed by Pfizer and Merck KGaA
03/25 Merck KGaA and Pfizer break into cancer immunotherapy
03/25 Pfizer, Merck KGaA score watershed FDA nod on cancer immunotherapy Bavencio
03/24 MERCK : Global Analyzer for Particle Counters Market- HCT Instruments, Honri, IQ..
03/23 MERCK : FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Ap..
03/23 PFIZER : FDA Grants Approval for BAVENCIO (avelumab)
03/23 PFIZER : FDA Grants Approval for BAVENCIO (avelumab), the First Immunotherapy Ap..
03/22 “BOLD & VIBRANT” : Merck KGaA, Darmstadt, Germany, Presents Innovati..
03/22 MERCK : unveils 2017 Darmstadt and Nairobi accelerator startups
03/21 MERCK : Introduces Mobius MyWay Portfolio for Customized Single-Use Assemblies
More news
Sector news : Specialty & Advanced Pharmaceuticals
02:38p FDA, Mylan silence on generic Advair may be good news for GSK
01:43p British business navigates rocky path to Brexit
09:52a ConvaTec's majority investors raise $1.2 billion via stake sale
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
03/28DJSHIRE : Files 8K - Other Events
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
03/23 FDA OKs Merck KGaA and Pfizer's avelumab for rare type of skin cancer
03/23 BeiGene, Another Beijing Venture In Cancer Therapy
03/10 Pfizer And Merck Go For An Even Longer Throw Of The Javelin
03/09 Merck KGaA's (MKGAF) CEO Stefan Oschmann on Q4 2016 Results - Earnings Call T..
03/09 Merck KGaA 2016 Q4 - Results - Earnings Call Slides
Advertisement
Financials (€)
Sales 2017 15 580 M
EBIT 2017 3 274 M
Net income 2017 1 846 M
Debt 2017 9 602 M
Yield 2017 1,24%
P/E ratio 2017 24,23
P/E ratio 2018 20,58
EV / Sales 2017 1,48x
EV / Sales 2018 1,30x
Capitalization 13 415 M
More Financials
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 110 €
Spread / Average Target 5,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA4.69%14 506
ABBVIE INC5.37%105 144
KYOWA HAKKO KIRIN CO L..8.78%9 127
JAZZ PHARMACEUTICALS P..33.83%8 717
CONVATEC GROUP PLC14.96%6 587
MALLINCKRODT PLC-11.02%4 641
More Results